These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34398971)

  • 1. A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
    Ji J; Liu Z; Kuang P; Dong T; Chen X; Li J; Zhang C; Liu J; Zhang L; Shen K; Liu T
    Int J Cancer; 2021 Dec; 149(12):2075-2082. PubMed ID: 34398971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
    Nieto Y; Valdez BC; Thall PF; Ahmed S; Jones RB; Hosing C; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Alousi A; Shah N; Bashir Q; Liu Y; Oki Y; Hagemeister F; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1914-20. PubMed ID: 26071868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
    Nieto Y; Valdez BC; Thall PF; Jones RB; Wei W; Myers A; Hosing C; Ahmed S; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Shah N; Bashir Q; Alousi A; Oki Y; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
    Cancer; 2016 Sep; 122(17):2680-8. PubMed ID: 27203405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
    Kim DY; Chung JS; Jo JC; Cho SH; Shin HJ
    Ann Hematol; 2020 Apr; 99(4):819-828. PubMed ID: 32025840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
    Escalón MP; Stefanovic A; Venkatraman A; Pereira D; Santos ES; Goodman M; Byrnes JJ; Fernandez HF
    Bone Marrow Transplant; 2009 Jul; 44(2):89-96. PubMed ID: 19169287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
    Sapelli J; Filho JS; Matias Vieira GM; Moura FL; Germano JN; de Lima VCC
    Leuk Res; 2021 Nov; 110():106689. PubMed ID: 34592699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
    Ji J; Valdez BC; Li Y; Liu Y; Teo EC; Nieto Y; Champlin RE; Andersson BS
    Exp Hematol; 2016 Jun; 44(6):458-65. PubMed ID: 26976752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
    Nieto Y; Thall P; Valdez B; Andersson B; Popat U; Anderlini P; Shpall EJ; Bassett R; Alousi A; Hosing C; Kebriaei P; Qazilbash M; Frazier E; Gulbis A; Chancoco C; Bashir Q; Ciurea S; Khouri I; Parmar S; Shah N; Worth L; Rondon G; Champlin R; Jones RB
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1677-86. PubMed ID: 22643322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation.
    Cao X; Li Z; Zhang Y; Cui Q; Dai H; Ma Y; Li M; Chen S; Yin J; Cui W; Chen J; Sun A; Qiu H; Chen S; Zhu X; Andersson BS; Wu D; Tang X
    Ann Hematol; 2024 Aug; 103(8):3083-3093. PubMed ID: 38900303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
    Arai S; Letsinger R; Wong RM; Johnston LJ; Laport GG; Lowsky R; Miklos DB; Shizuru JA; Weng WK; Lavori PW; Blume KG; Negrin RS; Horning SJ
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1145-54. PubMed ID: 20197102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Kang BW; Kim WS; Kim C; Jang G; Lee SS; Choi YH; Lee DH; Kim SW; Kim S; Ryu JS; Huh J; Lee JS; Suh C
    Invest New Drugs; 2010 Aug; 28(4):516-22. PubMed ID: 19547918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
    Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
    J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
    Nieto Y; Popat U; Anderlini P; Valdez B; Andersson B; Liu P; Hosing C; Shpall EJ; Alousi A; Kebriaei P; Qazilbash M; Parmar S; Bashir Q; Shah N; Khouri I; Rondon G; Champlin R; Jones RB
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):410-7. PubMed ID: 23128322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study.
    Andion M; Molina B; Gonzalez-Vicent M; Alonso L; Hernandez C; Lassaletta A; Lopez-Ibor B; Villa M; Diaz MA
    J Pediatr Hematol Oncol; 2011 Apr; 33(3):e89-91. PubMed ID: 21358341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.
    Grigg AP; Stone J; Milner AD; Schwarer AP; Wolf M; Prince HM; Seymour J; Gill D; Ellis D; Bashford J;
    Leuk Lymphoma; 2010 Apr; 51(4):641-9. PubMed ID: 20218809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma.
    Zeng Q; Zhang H; Kuang P; Li J; Chen X; Dong T; Wu Q; Zhang C; Chen C; Niu T; Liu T; Liu Z; Ji J
    Front Oncol; 2023; 13():1143556. PubMed ID: 36969020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.